[Polychemotherapy of non-small cell bronchial cancer with mitomycin C, ifosfamide and vindesine].
The results of antineoplastic polychemotherapy in non-small-cell carcinomas of the lungs revealed on overall remission rate of 42.1%, with a distribution from limited to extensive disease of approximately 32% to 58%. Severe undesired side effects of the treatment were not observed, the duration of remission was, on average, 78 days, and the survival period 101 days.
Laumen
R
R
Klinik Seltersberg, Giessen der LVA-Hessen.
Jungbluth
H
H
von Pawel
J
J
Häussinger
K
K
Otto
M
M
Krieger
H
H
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008175:Lung Neoplasms / Q000188:drug therapy*; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D014751:Vindesine / Q000008:administration & dosage
D008937:Mitomycins; D016685:Mitomycin; D014751:Vindesine; D007069:Ifosfamide
Polychemotherapie beim nicht kleinzelligen Bronchialkarzinom mit Mitomycin C, Ifosfamid und Vindesine.